KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $2.0 billion.

  • Eli Lilly's Accumulated Depreciation & Amortization rose 1301.64% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 1301.64%. This contributed to the annual value of $2.0 billion for FY2025, which is 1301.64% up from last year.
  • As of Q4 2025, Eli Lilly's Accumulated Depreciation & Amortization stood at $2.0 billion, which was up 1301.64% from $1.4 billion recorded in Q3 2025.
  • Eli Lilly's 5-year Accumulated Depreciation & Amortization high stood at $2.0 billion for Q4 2025, and its period low was $350.3 million during Q1 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $1.0 billion (2021), whereas its average is $1.0 billion.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 2803.36% in 2021, then crashed by 1684.65% in 2023.
  • Eli Lilly's Accumulated Depreciation & Amortization (Quarter) stood at $1.5 billion in 2021, then dropped by 1.62% to $1.5 billion in 2022, then rose by 0.3% to $1.5 billion in 2023, then increased by 15.72% to $1.8 billion in 2024, then increased by 13.02% to $2.0 billion in 2025.
  • Its last three reported values are $2.0 billion in Q4 2025, $1.4 billion for Q3 2025, and $941.3 million during Q2 2025.